CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer - PubMed (original) (raw)
. 2017 Jun;145(3):436-445.
doi: 10.1016/j.ygyno.2017.03.007. Epub 2017 Mar 17.
Affiliations
- PMID: 28318643
- DOI: 10.1016/j.ygyno.2017.03.007
CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer
Katrina K Au et al. Gynecol Oncol. 2017 Jun.
Abstract
Objective: We recently established that high STAT1 expression and associated T helper type I tumour immune microenvironment (TME) are prognostic and chemotherapy response predictive biomarkers in high-grade serous ovarian cancer (HGSC). STAT1 induced chemokine CXCL10 is key to the recruitment of lymphocytes in the TME and is significantly highly expressed in the tumours from patients with longer survival. In the current study we therefore aimed to elucidate the role CXCL10 in disease progression and tumour immune transcriptomic alterations using the ID8 syngeneic murine model of HGSC.
Methods: ID8 ovarian cancer cells were engineered for stable knockdown (KD) and overexpression (OX) of CXCL10. The OX and KD cell line derivatives, along with their respective vector controls, were implanted in immunocompetent C57BL/6 mice via intra-peritoneal injections. At end point, immune transcriptomic profiling of tumour tissues and multiplex cytokine profiling of ascites, was performed. Effect of CXCL10 expression on the tumour vasculature and tumour cell proliferation was evaluated by CD31 and Ki67 immunostaining, respectively.
Results: Increased CXCL10 expression led to decreased tumour burden and malignant ascites accumulation in the ID8 syngeneic murine model of HGSC. The ascites levels of IL-6 and VEGF were significantly reduced in OX mice compared to the vector controls. The OX tumours also showed reduced vasculature (CD31) and proliferative index (Ki67) compared to the control tumours. Significantly higher expression of genes associated with antigen processing, apoptosis and T cell function was observed in OX tumours compared to the controls. Reduced CXCL10 expression in tumours from KD mice led to increased ascites accumulation and disease progression compared to the controls.
Conclusion: CXCL10 is a positive determinant of anti-tumour immune responses in HGSC TME and disease progression. These findings are foundational for future translational studies aimed at improving treatment response and survival in HGSC patients, via exploiting the TME.
Keywords: CXCL10; ID8; Interferon; Ovarian cancer; Tumour immune microenvironment.
Copyright © 2017 Elsevier Inc. All rights reserved.
Similar articles
- A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M, Siu A, Clément I, Bidarimath M, Turashvili G, Edwards A, Rahimi K, Mes-Masson AM, Squire JA. Koti M, et al. Br J Cancer. 2015 Mar 31;112(7):1215-22. doi: 10.1038/bjc.2015.81. Br J Cancer. 2015. PMID: 25826225 Free PMC article. - STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
Ghaffari A, Peterson N, Khalaj K, Vitkin N, Robinson A, Francis JA, Koti M. Ghaffari A, et al. Br J Cancer. 2018 Aug;119(4):440-449. doi: 10.1038/s41416-018-0188-5. Epub 2018 Jul 26. Br J Cancer. 2018. PMID: 30046165 Free PMC article. - The peritoneal tumour microenvironment of high-grade serous ovarian cancer.
Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FN, Cooper D, Gould D, Ennis DP, Lockley M, McNeish IA, Nourshargh S, Balkwill FR. Leinster DA, et al. J Pathol. 2012 Jun;227(2):136-45. doi: 10.1002/path.4002. Epub 2012 Apr 18. J Pathol. 2012. PMID: 22322968 Free PMC article. - Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
Clifford C, Vitkin N, Nersesian S, Reid-Schachter G, Francis JA, Koti M. Clifford C, et al. Am J Reprod Immunol. 2018 Aug;80(2):e12975. doi: 10.1111/aji.12975. Epub 2018 May 21. Am J Reprod Immunol. 2018. PMID: 29781548 Review. - Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles.
May T, Shoni M, Crum CP, Xian W, Vathipadiekal V, Birrer M, Rosen B, Tone A, Murphy KJ. May T, et al. Gynecol Oncol. 2013 Mar;128(3):488-92. doi: 10.1016/j.ygyno.2012.12.009. Epub 2012 Dec 16. Gynecol Oncol. 2013. PMID: 23253401 Review.
Cited by
- Evidence for the presence of Borrelia burgdorferi in invasive breast cancer tissues.
Patel NJ, Thippani S, Jathan J, Gaur G, Sawant JY, Pandya JM, Sapi E. Patel NJ, et al. Eur J Microbiol Immunol (Bp). 2024 Mar 7;14(2):143-153. doi: 10.1556/1886.2024.00021. Print 2024 May 14. Eur J Microbiol Immunol (Bp). 2024. PMID: 38451280 Free PMC article. - Immunology and Immune Checkpoint Inhibition in Ovarian Cancer - Current Aspects.
Bronger H. Bronger H. Geburtshilfe Frauenheilkd. 2021 Oct;81(10):1128-1144. doi: 10.1055/a-1475-4335. Epub 2021 Jul 6. Geburtshilfe Frauenheilkd. 2021. PMID: 34629492 Free PMC article. - Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction.
Idorn M, Olsen M, Halldórsdóttir HR, Skadborg SK, Pedersen M, Høgdall C, Høgdall E, Met Ö, Thor Straten P. Idorn M, et al. Oncoimmunology. 2017 Dec 26;7(4):e1412029. doi: 10.1080/2162402X.2017.1412029. eCollection 2018. Oncoimmunology. 2017. PMID: 29632724 Free PMC article. - Identification of CXCL10-Relevant Tumor Microenvironment Characterization and Clinical Outcome in Ovarian Cancer.
Jin J, Li Y, Muluh TA, Zhi L, Zhao Q. Jin J, et al. Front Genet. 2021 Jul 27;12:678747. doi: 10.3389/fgene.2021.678747. eCollection 2021. Front Genet. 2021. PMID: 34386037 Free PMC article. - Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer.
Lu H, Lou H, Wengert G, Paudel R, Patel N, Desai S, Crum B, Linton-Reid K, Chen M, Li D, Ip J, Mauri F, Pinato DJ, Rockall A, Copley SJ, Ghaem-Maghami S, Aboagye EO. Lu H, et al. Cell Rep Med. 2023 Jul 18;4(7):101092. doi: 10.1016/j.xcrm.2023.101092. Epub 2023 Jun 21. Cell Rep Med. 2023. PMID: 37348499 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous